Clinical Trials

Tardive Dyskinesia

INGREZZA® (valbenazine) capsules received FDA approval on April 11, 2017, becoming the first medicine approved in the United States for the treatment of adults with tardive dyskinesia (TD), an involuntary movement disorder. The approval of INGREZZA was based on data from the KINECT 3 study, a Phase III, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study comparing once-daily INGREZZA 80mg and 40mg to placebo over six weeks in patients with moderate to severe tardive dyskinesia and an underlying schizophrenia, schizoaffective disorder or mood disorder. For more information on INGREZZA, please visit

INGREZZA was also evaluated in KINECT 4, an open-label, one-year Phase III safety and efficacy study of once-daily INGREZZA 40mg and 80mg doses in patients with moderate to severe TD and clinical diagnoses of schizophrenia, schizoaffective disorder or mood disorder. Primary results from the KINECT 4 study were reported in December 2017. Additional analyses are ongoing.

Neurocrine Biosciences is also conducting RE-KINECT, the largest real-world dyskinesia screening study, which was designed to better understand the potentially broad-reaching impact of symptoms of possible TD in patients treated with antipsychotic medications. Initial results from the study showed that 28 percent of patients who were clinically evaluated were determined to have clinician-confirmed possible TD. More than 50 percent of patients had movements impacting two or more body regions, including the upper and lower limbs, neck and trunk (not just the face and mouth). Additional analyses are ongoing.

Additionally, Neurocrine Biosciences is conducting a Phase IV post-marketing study (Kinected 2) to evaluate the potential for clinical dependence and withdrawal symptoms associated with INGREZZA. For more information on the Kinected 2 study, please visit

Congenital Adrenal Hyperplasia

Neurocrine Biosciences is conducting a Phase II proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of crinecerfont in adult patients with classic congenital adrenal hyperplasia (CAH). The interim results from this ongoing open-label, multiple-dose, dose-escalation study were reported in March 2019.

Neurocrine Biosciences is conducting a Phase II, open-label, multiple-dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of crinecerfont in pediatric female and male patients (14 to 17 years of age) with classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). For more information on this Phase II study of crinecerfont in pediatric patients with CAH (CAHlibrate Pediatric Study), please visit or

Parkinson’s Disease

NBIb-1817 is currently being evaluated in the Phase II RESTORE-1 trial in patients who have been diagnosed with Parkinson’s disease for at least four years, are not responding adequately to oral medications, and have at least three hours of OFF time during the day, as measured by a validated self-reported patient diary. For more information about the RESTORE-1 clinical trial, please visit

NBIb-1817 is being developed by Neurocrine Biosciences and Voyager Therapeutics as part of a strategic collaboration announced in January 2019.

Chorea Associated with Huntington’s Disease

Neurocrine Biosciences is conducting KINECT-HD, a multi-center randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy, safety and tolerability of valbenazine for the treatment of chorea in patients with Huntington’s disease (HD). HD is a hereditary progressive neurodegenerative disorder, in which many patients may experience chorea, a troublesome involuntary movement disorder. For more information on this Phase III study of valbenazine for the treatment of chorea associated with HD, please visit

New VMAT2 Inhibitor

Neurocrine Biosciences filed an Investigational New Drug (IND) application and completed dosing in the single ascending dose portion of a Phase I study designed to assess initial safety, tolerability and pharmacokinetics of a novel, internally discovered VMAT2 inhibitor. This compound has the potential to be used in the treatment of several neurology and/or psychiatry disorders. The multiple dosing portion of this Phase I study is ongoing and is expected to be completed during the first half of 2019.

Compassionate Use

Policy on expanded access to investigational medicines

Individuals interested in participating in clinical trials for Neurocrine Biosciences’ products may visit the “Pipeline” section of the website for information on ongoing clinical trials. At this time, Neurocrine Biosciences does not have an expanded access program that allows patients to have access to the Company’s investigational products prior to FDA approval. Neurocrine Biosciences will update this page as the Company grows and reassesses the approach to expanded access programs. If you have any questions, please contact